Gynecologic Neoplasms
11
0
1
8
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
9.1%
1 terminated out of 11 trials
88.9%
+2.4% vs benchmark
18%
2 trials in Phase 3/4
38%
3 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (11)
Impact of Preoperative Sleep Quality and Anxiety on Postoperative Outcomes in Abdominal Gynecologic Cancer Surgery
Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer
PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer
A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers
A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer
Negative Pressure Wound Therapy in Obese Gynecologic Oncology Patients
Thromboprophylaxis After Surgery for Gynecologic Malignancy in China
Effect of Outpatient Symptom Management on Gynecologic Oncology Patients Receiving Chemotherapy
Emerging From the Haze for Gynecologic Cancer Survivors
Augmented Pulse Pressure Variation to Predict Fluid Responsiveness in Open Laparotomy
Safety of Regular Diet as the First Meal in Patients Who Underwent Surgical Treatment for Gynecologic Cancer